Table 3. Statistical evaluation of the correlation between clinical/tumor-associated markers and the clinical outcome of the patients.
| Comparative marker | Cut-off value | Number of patients | Months ± SD | Endpoint | P value |
|---|---|---|---|---|---|
| ECOG | ≤1 >2 |
29 10 |
9,31 ± 2,27 2,41 ± 0,43 |
PFS | <0.001 |
| ECOG | ≤1 >2 |
29 10 |
17,04 ± 2,97 3,91 ± 0,74 |
OS | <0.001 |
| CEA | ≤ median value >median value |
19 17 |
11,05 ± 3,36 4,41 ± 0,78 |
PFS | 0.189 |
| ≤ median value >median value |
19 19 |
19,10 ± 4,19 7,42 ± 1,14 |
OS | 0.021 | |
| Sex | Male Female |
18 21 |
5.8 ± 7.2 8.05 ± 11.6 |
PFS | >0.25 |
| Male Female |
18 21 |
11.44 ± 10.1 11.8 ± 12.2 |
OS | > 0.25 | |
| Age (years) | <50 ≥50 |
7 32 |
3.71 ± 2.28 7.75 ± 10.59 |
PFS | >0.25 |
| <50 ≥50 |
7 32 |
10.7 ± 5.43 11.8 ± 12.11 |
OS | >0.25 | |
| HLA-A2 | Positive Negative |
15 20 |
7,46 ± 2,98 7,10 ± 2,00 |
PFS | 0.764 |
| Positive Negative |
15 20 |
12,16 ± 3,35 13,70 ± 2,93 |
OS | 0.684 | |
| K-ras status | Wild Type Mut |
22 19 |
8,77 ± 2,29 4,68 ± 1,58 |
PFS | 0.050 |
| Wild Type Mut |
22 19 |
15,98 ± 3,35 8,64 ± 2,31 |
OS | 0.160 |
Legend: ECOG, Eastern Cooperative Oncology Group performance status; CEA, Carcino-Embryonic Antigen; Mut, Mutated.